close 73% inwestorów detalicznych traci pieniądze podczas handlu CFD z tym dostawcą. Inwestowanie wiąże się z ryzykiem i nie jest odpowiednie dla wszystkich inwestorów. Kontrakty CFD są złożonymi instrumentami i wiążą się z dużym ryzykiem szybkiej utraty środków pieniężnych z powodu dźwigni finansowej. 73% rachunków inwestorów detalicznych notuje stratę pieniędzy podczas handlu kontraktami CFD z tym dostawcą. Upewnij się, czy rozumiesz, jak działają kontrakty CFD, i czy możesz pozwolić sobie na wysokie ryzyko utraty pieniędzy.
Change languagePolski
Pulpit

LLY

1,011.28

-2.39%↓

JNJ

202.37

-1.51%↓

ABBV

228.23

-0.06%↓

UNH

334.44

-0.4%↓

AZN

90.21

-0.67%↓

LLY

1,011.28

-2.39%↓

JNJ

202.37

-1.51%↓

ABBV

228.23

-0.06%↓

UNH

334.44

-0.4%↓

AZN

90.21

-0.67%↓

LLY

1,011.28

-2.39%↓

JNJ

202.37

-1.51%↓

ABBV

228.23

-0.06%↓

UNH

334.44

-0.4%↓

AZN

90.21

-0.67%↓

LLY

1,011.28

-2.39%↓

JNJ

202.37

-1.51%↓

ABBV

228.23

-0.06%↓

UNH

334.44

-0.4%↓

AZN

90.21

-0.67%↓

LLY

1,011.28

-2.39%↓

JNJ

202.37

-1.51%↓

ABBV

228.23

-0.06%↓

UNH

334.44

-0.4%↓

AZN

90.21

-0.67%↓

Strona główna・Stock List・Karyopharm Therapeutics Inc
Search

Karyopharm Therapeutics Inc

Open

SectorHealthcare

5.52 4.55

Strong Buy

Price update 4 gru 2025, 16:01 UTC

BuySell

Overview

Share price change

24h

Current

Min

5.26

Max

5.52

Key metrics

By Trading Economics

Income

4.1M

-33M

Sales

6.1M

44M

EPS

-3.82

Profit margin

-75.213

Employees

279

EBITDA

1.8M

-23M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+140.52% upside

Market Stats

By TradingEconomics

Market Cap

-4.2M

98M

Previous open

0.97

Previous close

5.52

News Sentiment

By Acuity

50%

50%

167 / 374 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Bullish Evidence

5.9501 / 7.66 Support & Resistance

Karyopharm Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

3 gru 2025, 23:21 UTC

Earnings
Acquisitions, Mergers, Takeovers

EQB to Buy Loblaw Unit PC Financial for About $573.5 Million -- Update

DJ

Read

3 gru 2025, 23:14 UTC

Acquisitions, Mergers, Takeovers

EQB to Buy PC Financial From Loblaw for About $573.5 Million

DJ

Read

3 gru 2025, 22:01 UTC

Major Market Movers

Costco Wholesale Reports Higher Monthly Sales

DJ

Read

3 gru 2025, 21:38 UTC

Earnings

Salesforce Raises Revenue Forecast as Agentforce Sales Top $500 Million

DJ

Read

3 gru 2025, 23:59 UTC

Market Talk

Australian Coal Prices Seen Having Recovered Well -- Market Talk

DJ

Read

3 gru 2025, 23:49 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

DJ

Read

3 gru 2025, 23:49 UTC

Market Talk

HSBC Chair Appointment Unlikely to Have Material Operational Impact -- Market Talk

DJ

Read

3 gru 2025, 23:49 UTC

Market Talk

Nikkei May Decline Amid Caution Over U.S. Labor Market -- Market Talk

DJ

Read

3 gru 2025, 23:13 UTC

Market Talk

Australian Treasurer Says Economy Not On Drip of Govt Spending -- Market Talk

DJ

Read

3 gru 2025, 23:10 UTC

Earnings

Salesforce Raises Forecast as Agentforce Sales Top $500M -- Update

DJ

Read

3 gru 2025, 23:08 UTC

Market Talk

Goodman's New Bull Sees Profit Upgrade on Cards -- Market Talk

DJ

Read

3 gru 2025, 23:06 UTC

Acquisitions, Mergers, Takeovers

EQB to Buy Loblaw Unit PC Financial for About $573.5M -- Update

DJ

Read

3 gru 2025, 22:59 UTC

Acquisitions, Mergers, Takeovers

EQB to Buy PC Financial From Loblaw for About $573.5M

DJ

Read

3 gru 2025, 22:45 UTC

Market Talk

WiseTech Investor Day Increases Bull's Confidence -- Market Talk

DJ

Read

3 gru 2025, 22:20 UTC

Earnings

Salesforce CEO: 9,500 of 18,500 Total Closed Agentforce Deals Are Paid

DJ

Read

3 gru 2025, 22:19 UTC

Earnings

Salesforce CEO: Six Out of 10 Biggest Deals in 3Q Came from Agentforce

DJ

Read

3 gru 2025, 22:17 UTC

Earnings

Salesforce Working to Add Voice to Agentforce, CEO Says

DJ

Read

3 gru 2025, 22:16 UTC

Earnings

Salesforce CEO: Williams-Sonoma's Agentforce Makes Up 60% of Customer Chats

DJ

Read

3 gru 2025, 22:15 UTC

Earnings

Salesforce CEO: Agentforce ARR Was $540M in 3Q

DJ

Read

3 gru 2025, 22:10 UTC

Acquisitions, Mergers, Takeovers

EQB: Will Enter Into a Long-Term Strategic Relationship With Loblaw >EQB.T

DJ

Read

3 gru 2025, 22:09 UTC

Acquisitions, Mergers, Takeovers

EQB: Agreed to Acquire PC Fincl From Loblaw >EQB.T

DJ

Read

3 gru 2025, 21:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

DJ

Read

3 gru 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

DJ

Read

3 gru 2025, 21:49 UTC

Earnings

Salesforce Reports Mounting Profits. The Stock Is Rising. -- Barrons.com

DJ

Read

3 gru 2025, 21:23 UTC

Earnings

Salesforce Raises Revenue Forecast as Agentforce Sales Top $500M

DJ

Read

3 gru 2025, 21:19 UTC

Earnings

Salesforce Reports Mounting Profits. The Stock Is Rising. -- Barrons.com

DJ

Read

3 gru 2025, 21:06 UTC

Earnings

Salesforce Reports Mixed Earnings. The Stock Is Rising. -- Barrons.com

DJ

Read

3 gru 2025, 21:04 UTC

Earnings

Salesforce Sees Profitable Growth Framework Target of 50 by FY30 >CRM

DJ

Read

3 gru 2025, 21:04 UTC

Earnings

Salesforce Targets $60 B Plus Organic Rev by FY30 >CRM

DJ

Read

3 gru 2025, 21:03 UTC

Earnings

Salesforce Raises FY26 Oper Cash Flow Growth Guidance to 13% to 14% Y/Y >CRM

DJ

Read

Peer Comparison

Price change

Karyopharm Therapeutics Inc Forecast

Price Target

By TipRanks

140.52% upside

12 Months Forecast

Average 13.83 USD  140.52%

High 21 USD

Low 6 USD

Based on 6 Wall Street analysts offering 12 month price targets forKaryopharm Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

6 ratings

5

Buy

1

Hold

0

Sell

Based on 6 analysts giving stock ratings to Karyopharm Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

5.9501 / 7.66Support & Resistance

Short Term

Bullish Evidence

Recent bullish events outweigh bearish events.

Intermediate Term

Strong Bearish Evidence

All events are bearish.

Long Term

No Evidence

There are no events.

Sentiment

By Acuity

167 / 374 Ranking in Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

Other stocks from the sector

LLY

Eli Lilly and Co.

1,011.28

↓-2.39%

JNJ

Johnson and Johnson

202.37

↓-1.51%

ABBV

AbbVie Inc

228.23

↓-0.06%

UNH

UnitedHealth Group Inc

334.44

↓-0.4%

AZN

AstraZeneca PLC ADR

90.21

↓-0.67%
help-icon Live chat